Profiling the role of m6A effectors in the regulation of pluripotent reprogramming
Wenjun Wang(First Affiliated Hospital of University of South China), Jiuwei Cui(Jilin University)
Cited by 2
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
|Biomarker Research|2020|473
Mechanisms of Cancer Resistance to Immunotherapy
|Frontiers in Oncology|2020|346